CÉSAR SANABRIA

Verified email at unmsm.edu.pe

Economista - Facultad de Ciencias Económicas
Universidad Nacional Mayor de San Marcos



                             

https://researchid.co/csanabriam

Economist, Master, and Doctor in Economics from the Universidad Nacional Mayor de San Marcos. Principal Professor of the Faculty of Economic Sciences and Member of the Institute of Economic Research of the UNMSM. He held management positions in the Public Sector: Social Security, Municipalities, and University. He has extensive experience consulting and researching social projects and policies and health economics. In addition, he teaches at the postgraduate level in public and private universities in the country and abroad. He has publications on topics of his specialization and extensive participation in academic events.

EDUCATION

Economics at Universidad Nacional Mayor de San Marcos
Master in Economics at Universidad Nacional Mayor de San Marcos
PhD in Economics from Universidad Nacional Mayor de San Marcos

RESEARCH INTERESTS

Health economics
Outcomes research
Social political

FUTURE PROJECTS

Determinantes socioeconómicos de la hipertensión en las mujeres del Perú

En el Perú las enfermedades prevalentes son ahora las crónicas y degenerativas y además se presentan en un marco de población que va envejeciendo (La mediana de la población es mayor a 37 años); el objetivo del estudio es establecer qué factores socioeconómicos y en qué estrato o grupo de población, se relacionan con la presencia de hipertensión y obesidad


Applications Invited
5

Scopus Publications

173

Scholar Citations

6

Scholar h-index

6

Scholar i10-index

Scopus Publications

  • Cost-effectiveness of interferon therapy for multiple sclerosis in Peru: impact of treatment adherence
    Rafael Bolaños-Díaz, César Sanabria-Montañez, and Nilton Custodio-Capuñay

    Journal of Pharmaceutical Health Services Research, ISSN: 17598885, eISSN: 17598893, Pages: 125-132, Published: March 2019 Oxford University Press (OUP)
    Abstract Objective To analyse the cost-effectiveness (C-E) of interferon therapy for MS and the impact of adherence associated with a patient support programme (PSP). Methods Markov model was structured based on systematic review of the evidence and the opinion of local experts. The model has three health states: (1) Baseline treatment (BT), (2) Interferon-β (IFN) with patient support programme (PSP) and (3) IFN without PSP. Annual cycles were considered, with a time horizon of 30 years. The analysis perspective was based on the Ministry of Health (MoH). Key findings Interferon-β + PSP dominates the treatment of IFN without PSP. The incremental C-E rate (ICER) for IFN + PSP was estimated at S/. 26 408 per Quality Adjusted Life Year (QALY) in relation to BT. IFN without PSP was dominated by the IFN + PSP treatment. The cost per QALY of IFN + PSP was below the payment threshold in almost 100% of the model simulations. The acceptability curves show that the treatment with PSP + IFN is probabilistically more cost effective from a payment threshold of 1.25 annual Gross Domestic Product per capita (GDP-pc). The Tornado analysis for the ICER between IFN + PSP and BT shows that the most sensitive variables of the model are the relative risk (RR) for treatment adherence and the cost of IFN + PSP treatment. Conclusion The addition of a PSP had a significant effect on adherence and C-E of the intervention. The ICER for IFN + PSP was below 1.5 annual GDP-pc of payment threshold with an incremental cost near to 3 GDP-pc. IFN without PSP was dominated by the IFN + PSP.

  • Cost-effectiveness of Cetuximab as a treatment strategy for metastatic colon cancer in Peru: chemotherapy/Cetuximab versus chemotherapy alone
    Rafael Bolaños-Díaz, César Sanabria-Montañez, Carlos Farfán-Tello, and María Calderón-Cahua

    Journal of Pharmaceutical Health Services Research, ISSN: 17598885, eISSN: 17598893, Pages: 319-326, Published: December 2018 Oxford University Press (OUP)
    To evaluate cost‐effectiveness – from a local perspective – of cetuximab when it is added to conventional chemotherapy for the treatment of metastatic colon cancer.

  • The process of health sector reform in Peru
    Pedro Jesús Mendoza-Arana, Germán Rivera-Del Río, César Gutiérrez-Villafuerte, and César Sanabria-Montáñez

    Revista Panamericana de Salud Publica/Pan American Journal of Public Health, ISSN: 10204989, eISSN: 16805348, Published: 2018 Pan American Health Organization
    Objective To characterize the process of health sector reform (HSR) in Peru (launched publicly in 2013), identifying the principal advances in its implementation and the pending challenges from the perspective of the participating actors. Methods This study systematizes experiences through semi-structured interviews conducted with 21 key informants, including three ex-ministers of health, using the decade 2005-2015 as the time frame. Official databases were analyzed to verify variations in health indicators. Results The proposed reform was based on expanding insurance coverage (predominantly public health insurance), following the structured pluralism model, with clear separation between the functions of delivery, financing, regulation, and governance. The main progress in HSR identified by this study involves: having transcended the poverty criterion for public insurance, strengthening investments in infrastructure and human resources, strengthening the National Health Authority with a focus on the rights of users, and reinforcing the public health role of the Ministry of Health. The main challenges involve providing non-poverty-related insurance coverage for the population, having sufficient specialized human resources, and reducing out-of-pocket expenditure. Conclusions In the 10 years under analysis, HSR is a process that builds on the progress made in prior years; a process that consolidates an insurance model aimed at universal coverage based on public health insurance and that has led to a demonstrable increase in public spending and population coverage. However, progress has been limited mainly due to insufficient provision of specialized human resources and out-of-pocket expenditure, which remains very high.

  • Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: Entecavir and tenofovir
    Rafael Bolaños-Díaz, Romina A. Tejada, César Sanabria, and Seimer Escobedo-Palza

    Revista Peruana de Medicina Experimental y Salud Publica, ISSN: 17264634, eISSN: 17264642, Pages: 377-385, Published: July-September 2017 Instituto Nacional de Salud (Peru)
    Objetives. To compare in terms of cost-effectiveness to entecavir (ETV) and tenofovir (TDF) in the treatment of hepatitis B virus (HBV) in public hospitals in Peru. Materials and methods. We structured a Markov model. We define effectiveness adjusted life years for quality (QALY). We include the direct costs of treatment in soles from the perspective of the Ministry of Health of Peru. We estimate the relationship between cost and effectiveness ratios (ICER). We performed sensitivity analyzes considering a range of willingness to pay (WTP) from one to three times the Gross Domestic Product (GDP) per capita, and a tornado analysis regarding Monetary Net Profit (BMN) or ICER. Results. Treatment with TDF is more effective and less expensive than ETV. The ETV had a cost per QALY of PEN 4482, and PEN 1526 TDF. The PTO maintains a progressively larger with increasing WTP BMN. The discount rate was the only variable with a significant effect on model uncertainty. Conclusion: Treatment with TDF is more cost-effective than ETV in public hospitals in Peru.

  • Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
    Edward Mezones-Holguín, Rafael Bolaños-Díaz, Víctor Fiestas, César Sanabria, Alfonso Gutiérrez-Aguado, Fabián Fiestas, Víctor J Suárez, Alfonso J. Rodriguez-Morales, and Adrián V Hernández

    Journal of Infection in Developing Countries, ISSN: 20366590, eISSN: 19722680, Pages: 1552-1562, Published: 1 December 2014 Journal of Infection in Developing Countries
    Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 years-old. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.

RECENT SCHOLAR PUBLICATIONS

  • Patrones de costos de atencin a pacientes con enfermedades isqumicas del corazn en el Instituto Nacional Cardiovascular, 2019
    C Sanabria-Montaez, J Cabrejos Polo, AR Olortegui Yzu, ...
    Anales de la Facultad de Medicina 83 (2), 104-111 2022

  • Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru
    R Bolaos-Daz, E Angles-Yanqui, G Prez-Lazo, C Sanabria-Montaez
    Journal of Pharmaceutical Health Services Research 13 (1), 2-8 2022

  • Factores determinantes de la demanda y anlisis costo efectividad de los servicios preventivos de salud del cncer crvico uterino en el Per
    CA Sanabria Montaez
    Universidad Nacional Mayor de San Marcos 2022

  • Determinantes de la Demanda de Servicios de Prevencin Secundaria del cncer cervicouterino en Per
    C Sanabria-Montaez
    Revista Peruana de Investigacin en Salud 5 (4), 297-303 2021

  • Cost-effectiveness of interferon therapy for multiple sclerosis in Peru: impact of treatment adherence
    R Bolaos-Daz, C Sanabria-Montaez, N Custodio-Capuay
    Journal of Pharmaceutical Health Services Research 10 (1), 125-132 2019

  • Cost-effectiveness of Cetuximab as a treatment strategy for metastatic colon cancer in Peru: chemotherapy/Cetuximab versus chemotherapy alone
    R Bolaos-Daz, C Sanabria-Montaez, C Farfn-Tello, ...
    Journal of Pharmaceutical Health Services Research 9 (4), 319-326 2018

  • El proceso de reforma del sector salud en Per
    PJ Mendoza-Arana, GRD Ro, C Gutirrez-Villafuerte, ...
    Revista Panamericana de Salud Pblica 42, e74 2018

  • The process of health sector reform in Peru/El proceso de reforma del sector salud en Peru/Processo de reforma da saude no Peru.
    PJ Mendoza-Arana, G Rivera-Del Rio, C Gutierrez-Villafuerte, ...
    Revista Panamericana de Salud Publica 42 (1), NA-NA 2018

  • The process of health sector reform in Peru
    P Jesus Mendoza-Arana, G Rivera-Del Rio, C Gutierrez-Villafuerte, ...
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH 42 2018

  • Costo-efectividad de dos terapias antivirales para hepatitis B crnica en el Per: entecavir y tenofovir
    R Bolaos-Daz, RA Tejada, C Sanabria, S Escobedo-Palza
    Revista Peruana de Medicina Experimental y Salud Pblica 34, 377-385 2017

  • Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
    E Mezones-Holgun, R Bolaos-Daz, V Fiestas, C Sanabria, ...
    The Journal of Infection in Developing Countries 8 (12), 1552-1562 2014

  • Costo efectividad de Abatacept en comparacin con otras terapias biolgicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han
    F Becerra Rojas, C Benites Chacaltana, E Aiello, C Zingoni, G Bergman, ...
    Acta Mdica Peruana 28 (4), 200-210 2011

  • COST EFFECTIVENESS OF ABATACEPT IN COMPARISON WITH OTHER BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED TO
    F Becerra Rojas, C Benites Chacaltana, EC Aiello, C Zingoni, G Bergman, ...
    VALUE IN HEALTH 14 (3), A129-A129 2011

  • PMS33 COST EFFECTIVENESS OF ABATACEPT IN COMPARISON WITH OTHER BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED
    FB Rojas, CB Chacaltana, EC Aiello, C Zingoni, G Bergman, P Drost, ...
    Value in Health 14 (3), A129 2011

  • Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with
    F Becerra Rojas, C Benites Chacaltana, E Aiello, C Zingoni, G Bergman, ...
    Acta Medica Peruana 28 (4), 200-210 2011

  • La demanda de televisin digital terrestre en el Per
    C Sanabria Montaez
    2009

  • Cost-effectiveness of hormone replacement therapy (HRT) Compared to isoflavones in post-menopausal osteoporosis.
    R Bolaos Daz, C Sanabria Montaez, J Francia Romero, C Puente
    Acta Medica Peruana 26 (1), 27-34 2009

  • Anlisis costo-efectividad de la terapia de reemplazo hormonal (TRH) frente a isoflavonas en osteoporosis posmenopusica
    R Bolaos Daz, C Sanabria Montaez, J Francia Romero, ...
    Acta Mdica Peruana 26 (1), 27-34 2009

  • Financiamiento de Programas Sociales El Caso del Programa de Comedores Populares en el Per
    CA Sanabria Montaez
    2007

  • Financiamiento de Programas Sociales
    C Sanabria
    El caso de Programas de Comedores Populares en el Per 2007

MOST CITED SCHOLAR PUBLICATIONS

  • El proceso de reforma del sector salud en Per
    PJ Mendoza-Arana, GRD Ro, C Gutirrez-Villafuerte, ...
    Revista Panamericana de Salud Pblica 42, e74 2018
    Citations: 25

  • Estudio de oferta de los servicios de salud en el Per y el anlisis de brechas 2003-2020
    M Madueo, C Sanabria
    Informe tcnico N026s. Bethesda, MD: Proyecto Socios para la Reformaplus del 2003
    Citations: 24

  • La demanda por servicios de salud. Una aproximacin terica
    C Montaez
    Revista de la facultad deficiencias econmicas de la UNMSM, 151-70 2002
    Citations: 22

  • Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
    E Mezones-Holgun, R Bolaos-Daz, V Fiestas, C Sanabria, ...
    The Journal of Infection in Developing Countries 8 (12), 1552-1562 2014
    Citations: 19

  • El Rol del Estado y la salud en el Per
    C Sanabria
    Revista de la Facultad de Ciencias Econmicas 5 (15), 79-94 2000
    Citations: 19

  • Anlisis de la Brecha entre Oferta y Demanda de Servicios de Salud para la Programacin de la Inversin Sectorial de Mediano Plazo
    M Madueo, J Alarcn, C Sanabria
    Lima: PHRplus Per 2003
    Citations: 16

  • Anlisis de la brecha entre oferta y demanda de servicios de salud para la programacin de la inversin sectorial de mediano plazo
    MM Davila, JA Villaverde, CS Montaez
    Parners for Health Reformplus 2003
    Citations: 6

  • The process of health sector reform in Peru/El proceso de reforma del sector salud en Peru/Processo de reforma da saude no Peru.
    PJ Mendoza-Arana, G Rivera-Del Rio, C Gutierrez-Villafuerte, ...
    Revista Panamericana de Salud Publica 42 (1), NA-NA 2018
    Citations: 5

  • Costo efectividad de Abatacept en comparacin con otras terapias biolgicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han
    F Becerra Rojas, C Benites Chacaltana, E Aiello, C Zingoni, G Bergman, ...
    Acta Mdica Peruana 28 (4), 200-210 2011
    Citations: 5

  • Financiamiento de Programas Sociales El Caso del Programa de Comedores Populares en el Per
    CAS Montaez
    Pensamiento Crtico 7, 021-033 2007
    Citations: 4

  • Estimacin de Costos de los servicios de Salud de la Red Chilca-Mala
    C Sanabria
    Lima 2005
    Citations: 4

  • La evaluacin econmica en salud y la toma de decisiones en Iberoamrica
    J ROVIRA, CSMCS MONTAEZ
    Rev. Fac. Cien. Ecn. Univ. Nac. Mayor de San Marcos 10 (28), 27-46 2005
    Citations: 4

  • Anlisis costo-efectividad de la terapia de reemplazo hormonal (TRH) frente a isoflavonas en osteoporosis posmenopusica
    R Bolaos Daz, C Sanabria Montaez, J Francia Romero, ...
    Acta Mdica Peruana 26 (1), 27-34 2009
    Citations: 3

  • Anlisis costo-efectividad de dos sistemas de comunicacin y reporte epidemiolgico en el Per
    CASM CSAR, S MONTAEZ
    Rev. Fac. Cien. Ecn. Univ. Nac. Mayor de San Marcos 10 (25), 219-236 2005
    Citations: 3

  • La Carga econmica de la enfermedad diarreica aguda en nios menores de 3 aos en localidades de la sierra y selva del Per
    JC Arca Vera
    Universidad Nacional Mayor de San Marcos 2005
    Citations: 3

  • Financiamiento de Programas Sociales El Caso del Programa de Comedores Populares en el Per
    CA Sanabria Montaez
    2007
    Citations: 2

  • Financiamiento de Programas Sociales
    C Sanabria
    El caso de Programas de Comedores Populares en el Per 2007
    Citations: 2

  • Marco para el anlisis de la seguridad social en el Per
    CAS Montaez
    Pensamiento Crtico 9, 151-170
    Citations: 2

  • Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru
    R Bolaos-Daz, E Angles-Yanqui, G Prez-Lazo, C Sanabria-Montaez
    Journal of Pharmaceutical Health Services Research 13 (1), 2-8 2022
    Citations: 1

  • Determinantes de la Demanda de Servicios de Prevencin Secundaria del cncer cervicouterino en Per
    C Sanabria-Montaez
    Revista Peruana de Investigacin en Salud 5 (4), 297-303 2021
    Citations: 1